The safety of treatments for prolactinomas

References

• Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485–534.
   PubMed Web of Science ®Google Scholar
• Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med. 2003;349:2035–2041.
   PubMed Web of Science ®Google Scholar
• Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet. 1998;352:1455–1461.
   PubMed Web of Science ®Google Scholar
• Cunnah D, Besser M. Management of prolactinomas. Clin Endocrinol. 1991;34:231–235.
   PubMed Web of Science ®Google Scholar
• Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005;8:3–6.
   PubMedGoogle Scholar
• Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769–4775.
   PubMed Web of Science ®Google Scholar
• Colao A, Sarno AD, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003;148:325–331.
   PubMed Web of Science ®Google Scholar
• Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol. 1994;41:359–364.
   PubMed Web of Science ®Google Scholar
• Kars M, Souverein PC, Herings RM, et al. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab. 2009;94:2729–2734.
   PubMed Web of Science ®Google Scholar
• Colao A. Pituitary tumors in childhood. In: New MI [ed], 2004. Available from: Endotext.org.
   Google Scholar
• Colao A, Loche S. Prolactinomas in children and adolescents. Endocr Dev. 2010;17:146–159.
   PubMedGoogle Scholar
• Burgess JR, Shepherd JJ, Parameswaran V, et al. Prolactinomas in a large kindred with multiple endocrine neoplasia type1: clinical features and inheritance pattern. J Clin Endocrinol Metab. 1996;81:1841–1845.
   PubMed Web of Science ®Google Scholar
• Vergès B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 [MEN1]: data from the France–Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002;87:457–465.
   PubMed Web of Science ®Google Scholar
• De Laat JM, Dekkers OM, Pieterman CRC, et al. Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 study group (DMSG). J Clin Endocrinol Metab. 2015;100(9):3288–3296.
   PubMed Web of Science ®Google Scholar
• Burrow GN, Wortzman G, Rewcastle NB, et al. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med. 1981;304:156–158.
   PubMed Web of Science ®Google Scholar
• Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65:265–273.
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva FF, Hoffman AR, et al.; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288.
   PubMed Web of Science ®Google Scholar
• Colao A. The prolactinoma. Best Pract Res Clin Endocrinol Metab. 2009;23:575–596.
   PubMed Web of Science ®Google Scholar
• Klibanski A. Clinical practice. Prolactinomas. N Engl J Med. 2010;362(13):1219–1226.
   PubMed Web of Science ®Google Scholar
• Scanlon MF, Peters JR, Thomas JP, et al. Management of selected patients with hyperprolactinaemia by partial hypophysectomy. BMJ. 1985;291:1547–1550.
   PubMed Web of Science ®Google Scholar
• Serri O, Rasio E, Beauregard H, et al. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med. 1983;309:280–283.
   PubMed Web of Science ®Google Scholar
• Ciccarelli E, Ghigo E, Miola C, et al. Long-term follow-up of ‘cured’ prolactinoma patients after successful adenomectomy. Clin Endocrinol. 1990;32:583–592.
   PubMed Web of Science ®Google Scholar
• Massoud F, Serri O, Hardy J, et al. Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Surg Neurol. 1996;45:341–346.
   PubMedGoogle Scholar
• Thomson JA, Gray CE, Teasdale GM. Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up. Neurosurgery. 2002;50:36–39. discussion 39–40
   PubMed Web of Science ®Google Scholar
• Laws ER Jr, Thapar K. Pituitary surgery. Endocrinol Metab Clin North Am. 1999;28:119–131.
   PubMed Web of Science ®Google Scholar
• Zervas NT. Surgical results for pituitary adenomas: results of an international survey. In: Black PM, Zervas NT, Ridgway EC, et al., editors. Secretory tumors of the pituitary gland. New York (NY): Raven Press; 1984. p. 377–385.
   Google Scholar
• Barker FG 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab. 2003;88:4709–4719.
   PubMed Web of Science ®Google Scholar
• Sudhakar N, Ray A, Vafidis JA. Complications after trans-sphenoidal surgery: our experience and a review of the literature. Br J Neurosurg. 2004;18:507–512.
   PubMed Web of Science ®Google Scholar
• Nelson AT Jr, Tucker HS Jr, Becker DP. Residual anterior pituitary function following transsphenoidal resection of pituitary macroadenomas. J Neurosurg. 1984;61:577–580.
   PubMed Web of Science ®Google Scholar
• Barrow DL, Tindall GT. Loss of vision after transsphenoidal surgery. Neurosurgery. 1990;27:60–68.
   PubMed Web of Science ®Google Scholar
• Landolt AM, Lomax N. Gamma knife radiosurgery for prolactinomas. J Neurosurg. 2000;93(Suppl. 3)::14–18.
   PubMed Web of Science ®Google Scholar
• Elhateer H, Muanza T, Roberge D, et al. Fractionated stereotactic radiotherapy in the treatment of pituitary macroadenomas. Curr Oncol. 2008;15:286–292.
   PubMed Web of Science ®Google Scholar
• Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357:425–431.
   PubMed Web of Science ®Google Scholar
• Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31:301–342.
   PubMed Web of Science ®Google Scholar
• Tsang RW, Brierley JD, Panzarella T, et al. Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 1994;30:557–565.
   PubMed Web of Science ®Google Scholar
• Littley MD, Shalet SM, Beardwell CG, et al. Radiation-induced hypopituitarism is dose-dependent. Clin Endocrinol (Oxf). 1989;31:363–373.
   PubMed Web of Science ®Google Scholar
• Brada M, Burchell L, Ashley S, et al. The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Phys. 1999;45:693–698.
   PubMed Web of Science ®Google Scholar
• Minniti G, Traish D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab. 2005;90:800–804.
   PubMed Web of Science ®Google Scholar
• Erridge SC, Conkey DS, Stockton D, et al. Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol. 2009;93:597–601.
   PubMed Web of Science ®Google Scholar
• Cohen-Inbar O, Xu Z, Schlesinger D, et al. Gamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary. 2015;18(6):820–830.
   PubMed Web of Science ®Google Scholar
• Liu X, Kano H, Kondziolka D, et al. Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas. Pituitary. 2013;16(1):68–75.
   PubMed Web of Science ®Google Scholar
• Biller BMK, Colao A, Petersenn S, et al. Prolactinomas, Cushing’s disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord. 2010;10:10.
   PubMed Web of Science ®Google Scholar
• Holt RI, Barnett AH, Bailey CJ. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab. 2010;12(12):1048–1057.
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Pivonello R, et al. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs. 2002;11:787–800.
   PubMed Web of Science ®Google Scholar
• Klibanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1986;315:542–546.
   PubMed Web of Science ®Google Scholar
• Di Somma C, Colao A, Di Sarno A, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab. 1998;83:807–813.
   PubMed Web of Science ®Google Scholar
• De Rosa M, Colao A, Di Sarno A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol. 1998;138:286–293.
   PubMed Web of Science ®Google Scholar
• Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet. 2003;42(7):633–645.
   PubMed Web of Science ®Google Scholar
• Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001;86:5256–5261.
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Di Somma C, et al. Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord. 2009;10(2):111–123.
   PubMed Web of Science ®Google Scholar
• Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naïve patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. 2000;85:2247–2252.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Granieri L, Galdiero M, et al. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology. 2013;98(4):299–310.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Galdiero M, Vitale P, et al. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology. 2015;101(1):66–81.
   PubMed Web of Science ®Google Scholar
• Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996;14:228–238.
   PubMed Web of Science ®Google Scholar
• Kissner DG, Jarrett JC. Side effects of bromocriptine. N Engl J Med. 1980;302:749–750.
   PubMed Web of Science ®Google Scholar
• Turner TH, Cookson JC, Wass JA, et al. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J (Clin Res Ed). 1984;289:1101–1103.
   PubMed Web of Science ®Google Scholar
• Leong KS, Foy PM, Swift AC, et al. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxf). 2000;52:43–49.
   PubMed Web of Science ®Google Scholar
• Lam G, Mehta V, Zada G. Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature. Neurosurg Focus. 2012;32(6):E2. doi:10.3171/2012.4.FOCUS1268.
   Google Scholar
• Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994;331:904–909.
   PubMed Web of Science ®Google Scholar
• Bhatt MH, Keenan SP, Fleetham JA, et al. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol. 1991;30:613–616.
   PubMed Web of Science ®Google Scholar
• Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson’s disease with a long-acting ergot derivative, cabergoline. Eur Respir J. 1992;5:263–265.
   PubMed Web of Science ®Google Scholar
• Guptha SH, Promnitz AD. Pleural effusion and thickening due to cabergoline use in a patient with Parkinson’s disease. Eur J Intern Med. 2005;16:129–131.
   PubMedGoogle Scholar
• Ling LH, Ahlskog JE, Munger TM, et al. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson’s disease. Mayo Clin Proc. 1999;74:371–375.
   PubMed Web of Science ®Google Scholar
• Bancos I, Nannenga MR, Bostwick JM, et al. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf). 2014;80(6):863–868.
   PubMed Web of Science ®Google Scholar
• Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363:1179–1183.
   PubMed Web of Science ®Google Scholar
• Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356:29–38.
   PubMed Web of Science ®Google Scholar
• Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356:39–46.
   PubMed Web of Science ®Google Scholar
• Valassi E, Klibanski A, Biller BMK. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 2010;95:1025–1033.
   PubMed Web of Science ®Google Scholar
• Kars M, Pereira AM, Bax JJ, et al. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol. 2008;159:363–367.
   PubMed Web of Science ®Google Scholar
• Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot- and nonergot-derived dopamine agonists. Mov Disord. 2009;24:129–133.
   PubMed Web of Science ®Google Scholar
• Redfield MM, Nicholson WJ, Edwards WD, et al. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med. 1992;117:50–52.
   PubMed Web of Science ®Google Scholar
• Jahnichen S, Horowski R, Pertz HH. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol. 2005;513:225–228.
   PubMed Web of Science ®Google Scholar
• Lancellotti P, Livadariu E, Markov M, et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol. 2008;159:1–5.
   PubMed Web of Science ®Google Scholar
• Devin JK, Lakhani VT, Byrd BF 3rd, et al. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract. 2008;14:672–677.
   PubMedGoogle Scholar
• Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinomas. J Clin Endocrinol Metab. 2008;93:3348–3356.
   PubMed Web of Science ®Google Scholar
• Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008;93:3777–3784.
   PubMed Web of Science ®Google Scholar
• Wakil A, Rigby AS, Clark AL, et al. Low dose of cabergoline for hyperprolactinemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008;159:R11–R14.
   Web of Science ®Google Scholar
• Bogazzi F, Buralli S, Manetti L, et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinemia. Int J Clin Pract. 2008;62:1864–1869.
   PubMed Web of Science ®Google Scholar
• Herring N, Szmigielski C, Becher H, et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinomas. Clinendocrinol (Oxf). 2009;70:104–108.
   PubMed Web of Science ®Google Scholar
• Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009;12:153–157.
   PubMed Web of Science ®Google Scholar
• Nachtigall L, Valassi E, Lo J, et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf). 2010;72:53–58.
   PubMed Web of Science ®Google Scholar
• Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol. 2010;73:369–374.
   PubMed Web of Science ®Google Scholar
• Boguszewski CL, dos Santos CM, Sakamoto KS, et al. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary. 2012;15:44–49.
   PubMed Web of Science ®Google Scholar
• Delgado V, Biermasz NR, van Thiel SW, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol. 2012;77:99–105.
   PubMed Web of Science ®Google Scholar
• Elenkova A, Shabani R, Kalinov K, et al. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol. 2012;167:17–25.
   PubMed Web of Science ®Google Scholar
• Halperin I, Aller J, Varela C, et al. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinomas. Clin Endocrinol. 2012;77:275–280.
   PubMed Web of Science ®Google Scholar
• Córdoba-Soriano JG, Lamas-Oliveira C, Hidalgo-Olivares VM, et al. Valvular heart disease in hyperprolactinemic patients treated with low doses of cabergoline. Rev Esp Cardiol. 2013;66(5):410–412.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Pivonello R, Perone Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013;169(3):359–366.
   PubMed Web of Science ®Google Scholar
• Drake WM, Stiles CE, Howlett TA, et al.; UK Dopamine Agonist Valvulopathy Group. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab. 2014;99(1):90–96.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Pivonello R, Ferreri L, et al. Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am. 2015;44(1):89–97.
   PubMed Web of Science ®Google Scholar
• Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspidal, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83:897–902.
   PubMed Web of Science ®Google Scholar
• Trifirò G, Mokhles MM, Dieleman JP, et al. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson’s disease and hyperprolactinaemia: a multi-country, nested case-control study. Drug Saf. 2012;35:159–171.
   PubMed Web of Science ®Google Scholar
• Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonists treatment in Parkinson’s disease. Lancet Neurol. 2007;6:826–829.
   PubMed Web of Science ®Google Scholar
• Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol. 2015;3(11):906–913.
   PubMed Web of Science ®Google Scholar
• Bigazzi M, Ronga R, Lancranjan I, et al. A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal and amniotic compartments. J Clin Endocrinol Metab. 1979;48:9–12.
   PubMed Web of Science ®Google Scholar
• Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172(5):R205–R213.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Perone Y, Di Sarno A, et al. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab. 2013;98(1):372–379.
   PubMed Web of Science ®Google Scholar
• Glezer A, Bronstein MD. Prolactinomas, cabergoline, and pregnancy. Endocrine. 2014;47(1):64–69.
   PubMed Web of Science ®Google Scholar
• Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 2001;54(3):295–300.
   PubMed Web of Science ®Google Scholar
• Faje AT, Klibanski A. The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons. Endocrine. 2015;48(1):79–82.
   PubMed Web of Science ®Google Scholar
• Dallabonzana D, Spelta B, Oppizzi G, et al. Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases. J Endocrinol Invest. 1983;6:47–50.
   PubMed Web of Science ®Google Scholar
• Breidahl HD, Topliss DJ, Pike JW. Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. Br Med J (Clinical Research Ed). 1983;287:451–452.
   PubMed Web of Science ®Google Scholar
• Winkelmann J, Pagotto U, Theodoropoulou M, et al. Retention of dopamine 2 receptor mRNA and absence of the protein in craniospinal and extracranial metastasis of a malignant prolactinoma: a case report. Eur J Endocrinol. 2002;146:81–88.
   PubMed Web of Science ®Google Scholar
• Delgrange E, Crabbe J, Donckier J. Late development of resistance to bromocriptine in a patient with macro-prolactinoma. Horm Res. 1998;49:250–253.
   PubMed Web of Science ®Google Scholar
• Devin JK, Lakhani VT, Byrd BF 3rd, et al. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract. 2008;14:672–677.
   PubMedGoogle Scholar
• Selman WR, Laws ER Jr, Scheithauer BW, et al. The occurrence of dural invasion in pituitary adenomas. J Neurosurg. 1986;64:402–407.
   PubMed Web of Science ®Google Scholar
• Trouillas J, Raverot G, Jouanneau E, et al. Chapter 23: Tumeurs de l’hypophyse. In: Jean-Pierre D, Isabelle R-C, Peix J-L, editors. Tumeurs malignes rares. 1st ed. Lyon, 2010; XXII, p. 441, 632.
   Google Scholar
• Raverot G, Castinetti F, Jouanneau E, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf). 2012;76(6):769–775.
   PubMed Web of Science ®Google Scholar
• De Lellis RA, Lloyd RV, Heitz PU, et al., editors. World health organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004.
   Google Scholar
• Kaltsas GA, Nomikos P, Kontogeorgos G, et al. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005;90(5):3089–3099.
   PubMed Web of Science ®Google Scholar
• Colao A, Ochoa AS, Auriemma RS, et al. Pituitary carcinomas. Front Horm Res. 2010;38:94–108.
   PubMed Web of Science ®Google Scholar
• Lim S, Shahinian H, Maya MM, et al. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol. 2006;7(6):518–520.
   PubMed Web of Science ®Google Scholar
• Zacharia BE, Gulati AP, Bruce JN, et al. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory cushing’s disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery. 2014 Apr;74(4):E447–55.
   PubMed Web of Science ®Google Scholar
• Tatar Z, Thivat E, Planchat E, et al. Temozolomide and unusual indications: review of literature. Cancer Treat Rev. 2013;39(2):125–135.
   PubMed Web of Science ®Google Scholar
• Ortiz LD, Syro LV, Scheithauer BW, et al. Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo). 2012;67 Suppl 1:119–123.
   PubMed Web of Science ®Google Scholar
• Whitelaw BC, Dworakowska D, Thomas NW, et al. Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf). 2012;76(6):877–886.
   PubMed Web of Science ®Google Scholar
• McCormack AI, Wass JAH, Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest. 2011;41(10):1133–1148.
   PubMed Web of Science ®Google Scholar
• Colao A, Grasso LFS, Pivonello R, et al. Therapy of aggressive pituitary tumors. Expert Opin Pharmacother. 2011;12(10):1561–1570.
   PubMed Web of Science ®Google Scholar
• Dillard TH, Gultekin SH, Delashaw JB Jr, et al. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary. 2011;14(1):80–91.
   PubMed Web of Science ®Google Scholar
• Losa M, Mazza E, Terreni MR, et al. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol. 2010;163(6):843–851.
   PubMed Web of Science ®Google Scholar
• Syro LV, Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer. 2011;117(3):454–462.
   PubMed Web of Science ®Google Scholar
• Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010;95(10):4592–4599.
   PubMed Web of Science ®Google Scholar
• Maïza JC, Caron P. Pituitary carcinomas and aggressive adenomas: an overview and new therapeutic options. Ann Endocrinol (Paris). 2009;70 Suppl 1:S12–S19.
   Google Scholar
• Hagen C, Schroeder HD, Hansen S, et al. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol. 2009;161(4):631–637.
   PubMed Web of Science ®Google Scholar
• Widhalm G, Wolfsberger S, Preusser M, et al. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? Cancer. 2009;115(5):1070–1080.
   PubMed Web of Science ®Google Scholar
• Buchfelder M. Management of aggressive pituitary adenomas: current treatment strategies. Pituitary. 2009;12(3):256–260.
   PubMed Web of Science ®Google Scholar
• Fadul CE, Kominsky AL, Meyer LP, et al. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg. 2006;105(4):621–626.
   PubMed Web of Science ®Google Scholar
• McCormack AI, McDonald KL, Gill AJ, et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf). 2009;71(2):226–233.
   PubMed Web of Science ®Google Scholar
• Moraes AB, Silva CM, Vieira Neto L, et al. Giant prolactinomas: the therapeutic approach. Clin Endocrinol (Oxf). 2013;79(4):447–456.
   PubMed Web of Science ®Google Scholar
• Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010;116:2868–2877.
   PubMed Web of Science ®Google Scholar
• Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther. 2001;1:13–19.
   PubMedGoogle Scholar
• Guilleminault L, Carre P, Diot P. Hypersensitivity pneumonitis associated with temozolomide. Eur Respir J. 2009;34:526.
   PubMed Web of Science ®Google Scholar
• Sarma N. Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. Am J Clin Dermatol. 2009;10:264–267.
   PubMed Web of Science ®Google Scholar
• Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13:2986–2991.
   PubMed Web of Science ®Google Scholar
• Molitch ME. Management of medically refractory prolactinoma. J Neurooncol. 2014;117:421–428.
   PubMed Web of Science ®Google Scholar